Products

Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789 -02-8

China Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8, Find details about China Rivaroxaban, CAS 366789-02-8 from Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8

Model NO.
Rivaroxaban
Product Name
Rivaroxaban
CAS No.
366789-02-8
Mf
C19h18cln3o5s
MW
435.88
Sample
Available
Shipping
Prompt Delivery
Trademark
Senwayer
Transport Package
Foil Bag
Specification
1kg/bag
Origin
Wuhan, China
HS Code
29224995
Model NO.
Rivaroxaban
Product Name
Rivaroxaban
CAS No.
366789-02-8
Mf
C19h18cln3o5s
MW
435.88
Sample
Available
Shipping
Prompt Delivery
Trademark
Senwayer
Transport Package
Foil Bag
Specification
1kg/bag
Origin
Wuhan, China
HS Code
29224995

Anticoagulant and antithrombotic drugs Rivaroxaban CAS 366789-02-8
Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8
 
Product NameRivaroxaban
CAS No.366789-02-8
Molecular formulaC19H18ClN3O5S
Molecular weight435.88
Purity98%

 Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert its activity. Factor X is activated by endogenous and exogenous pathways as factor Xa (FXa), which plays an important role in the coagulation cascade.
 
Rivaroxaban inhibits the activity of factor Xa in a dose-dependent manner in humans. The prothrombin time (PT) and activated partial thromboplastin time (aPTT) measured by Neoplastin® reagent and the quantitative detection of HepTest® heparin showed a dose-dependent prolongation. The anti-Xa factor activity is also affected by rivaroxaban.

 
Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8
New anticoagulants were first used for thrombosis prevention after orthopedic surgery, including total hip and knee replacement surgery, and studies have reported that their effectiveness and safety are not inferior to low-molecular-weight heparin. Nowadays, new anticoagulants are gradually being widely used in the treatment of lower extremity venous thrombosis and pulmonary embolism. In 2014, the latest guidelines for the diagnosis and treatment of acute pulmonary embolism formulated by the ESC mentioned that new anticoagulants can be used as an emerging anticoagulant. Instead of traditional anticoagulation treatments, it will gradually be promoted in high-risk cardiovascular diseases such as atrial fibrillation and acute coronary syndrome.


Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8
Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8

You Might Also Like